GT Biopharma Q2 EPS $(0.05) Beats $(0.10) Estimate
Portfolio Pulse from Happy Mohamed
GT Biopharma reported Q2 losses of $(0.05) per share, beating the analyst consensus estimate of $(0.10) by 50%. This is a 50% increase over losses from the same period last year.
August 07, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GT Biopharma's Q2 losses were less than expected, which could positively impact the stock price in the short term.
GT Biopharma reported lower than expected losses for Q2, which is generally seen as positive news by investors. This could lead to increased demand for the stock, potentially driving up the price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100